Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Nasir Shah, Vlado Perkovic & Sradha Kotwal. (2022) Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria. Expert Review of Clinical Pharmacology 15:7, pages 827-842.
Read now
Read now
Ashish Sarraju, Gabriela Spencer-Bonilla, Fatima Rodriguez & Kenneth W Mahaffey. (2021) Canagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Future Cardiology 17:1, pages 39-48.
Read now
Read now
Dalal Y Al-Bazz & John PH Wilding. (2020) Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes. Future Cardiology 16:2, pages 77-88.
Read now
Read now
Haroon Jakher, Tara I Chang, Marilyn Tan & Kenneth W Mahaffey. (2019) Canagliflozin review – safety and efficacy profile in patients with T2DM. Diabetes, Metabolic Syndrome and Obesity 12, pages 209-215.
Read now
Read now
André J Scheen. (2019) An update on the safety of SGLT2 inhibitors. Expert Opinion on Drug Safety 18:4, pages 295-311.
Read now
Read now
Theodosios Filippatos, Eleftheria Tzavella, Christos Rizos, Moses Elisaf & George Liamis. (2017) Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. Expert Opinion on Drug Safety 16:10, pages 1121-1132.
Read now
Read now
Vasilios Tsimihodimos, Theodosios D. Filippatos & Moses S. Elisaf. (2017) Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. Expert Opinion on Drug Metabolism & Toxicology 13:4, pages 399-408.
Read now
Read now
Christian W. Mende. (2017) Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Current Medical Research and Opinion 33:3, pages 541-551.
Read now
Read now
Thomas C. Blevins & Azeez Farooki. (2017) Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Postgraduate Medicine 129:1, pages 159-168.
Read now
Read now
Articles from other publishers (44)
Xin Wang, Fengyi Zhang, Yufeng Zhang, Jiayi Zhang, Yingli Sheng, Wenbo Wang & Yujie Li. (2023) Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Osteoporosis International 34:12, pages 2013-2025.
Crossref
Crossref
Joshua Solomon, Maria Carolina Festa, Yiannis S. Chatzizisis, Ratna Samanta, Rita S. Suri & Thomas A. Mavrakanas. (2023) Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease. Pharmacology & Therapeutics 242, pages 108330.
Crossref
Crossref
Nancy Zaghloul, Ahmed Awaisu, Ahmed Mahfouz, Sumaya Alyafei & Hazem Elewa. (2022) A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country. International Journal of Clinical Pharmacy 44:6, pages 1342-1350.
Crossref
Crossref
Bingzi Dong, Ruolin Lv, Jun Wang, Lin Che, Zhongchao Wang, Zhouyang Huai, Yangang Wang & Lili Xu. (2022) The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture. Frontiers in Endocrinology 13.
Crossref
Crossref
Miles Fisher,Andrea Llano, and & Gerry McKay. 2022. Diabetes Drug Notes. Diabetes Drug Notes
95
129
.
Jun-Li Tsai, Cheng-Hsu Chen, Ming-Ju Wu & Shang-Feng Tsai. (2022) New Approaches to Diabetic Nephropathy from Bed to Bench. Biomedicines 10:4, pages 876.
Crossref
Crossref
Anna Masajtis-Zagajewska, Tomasz Hołub, Katarzyna Pęczek, Agnieszka Makówka & Michał Nowicki. (2021) Different Effects of Empagliflozin on Markers of Mineral-Bone Metabolism in Diabetic and Non-Diabetic Patients with Stage 3 Chronic Kidney Disease. Medicina 57:12, pages 1352.
Crossref
Crossref
D. A. Lebedev, N. V. Timkina, T. L. Karonova, A. T. Andreeva, M. A. Kokina, A. L. Grigorieva, A. Yu. Babenko & E. N. Grineva. (2021) Effect of empagliflozin on phosphorus and calcium metabolism in patients with type 2 diabetes mellitus with preserved kidney function. Osteoporosis and Bone Diseases 24:1, pages 4-9.
Crossref
Crossref
Thomas M. Caparrotta, Andrew M. Greenhalgh, Karen Osinski, Robert M. Gifford, Svenja Moser, Sarah H. Wild, Rebecca M. Reynolds, David J. Webb & Helen M. Colhoun. (2021) Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Therapy 12:4, pages 991-1028.
Crossref
Crossref
Joaquim Silva CustódioJrJr, Jarbas Roriz-Filho, Catarina Addobbati Jordão Cavalcanti, Amanda Martins & João Eduardo Nunes Salles. (2020) Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects. Drugs & Aging 37:6, pages 399-409.
Crossref
Crossref
Holly MabillardJohn A. Sayer. (2020) SGLT2 inhibitors – a potential treatment for Alport syndrome. Clinical Science 134:4, pages 379-388.
Crossref
Crossref
Jakob Starup-Linde & Søren Gregersen. 2020. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
411
436
.
Salvatore Carbone & Dave L. Dixon. (2019) The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Sruthi Adimadhyam, Todd A. Lee, Gregory S. Calip, Daphne E. Smith Marsh, Brian T. Layden & Glen T. Schumock. (2019) Sodium‐glucose co‐transporter 2 inhibitors and the risk of fractures: A propensity score‐matched cohort study. Pharmacoepidemiology and Drug Safety 28:12, pages 1629-1639.
Crossref
Crossref
Niki Katsiki & Dimitri P. Mikhailidis. (2019) Iron absorption, bone marrow fat and hematopoiesis in heart failure: Additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)?. Journal of Diabetes and its Complications 33:11, pages 107408.
Crossref
Crossref
L. Cheng, Y.-Y. Li, W. Hu, F. Bai, H.-R. Hao, W.-N. Yu & X.-M. Mao. (2019) Risk of bone fracture associated with sodium–glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials. Diabetes & Metabolism 45:5, pages 436-445.
Crossref
Crossref
Zien Zhou, Meg Jardine, Vlado Perkovic, David R. Matthews, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, Mehul Desai, Richard Oh, Roger Simpson, Nelson B. Watts & Bruce Neal. (2019) Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia 62:10, pages 1854-1867.
Crossref
Crossref
Joanna Sophia J. Vinke, Hiddo J.L. Heerspink & Martin H. de Borst. (2019) Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus. Current Opinion in Nephrology and Hypertension 28:4, pages 321-327.
Crossref
Crossref
Mahakpreet Singh, Ruchika Sharma & Anoop Kumar. (2019) Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus. Current Drug Safety 14:2, pages 87-93.
Crossref
Crossref
Silvina Gallo, Bernard Charbonnel, Allison Goldman, Harry Shi, Susan Huyck, Amanda Darekar, Brett Lauring & Steven G. Terra. (2019) Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial. Diabetes, Obesity and Metabolism 21:4, pages 1027-1036.
Crossref
Crossref
Evangelia Kalaitzoglou, John L. Fowlkes, Iuliana Popescu & Kathryn M. Thrailkill. (2018) Diabetes pharmacotherapy and effects on the musculoskeletal system. Diabetes/Metabolism Research and Reviews 35:2.
Crossref
Crossref
Riobaldo Cintra, Filipe A Moura, Luis Sergio F de Carvalho, Joaquim Barreto, Marcos Tambascia, Roberto Pecoits-Filho & Andrei C. Sposito. (2019) Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. Revista da Associação Médica Brasileira 65:1, pages 70-86.
Crossref
Crossref
Susan L. Wenker & Denise L. Walbrandt Pigarelli. (2019) Pharmacologic and Exercise Considerations in Older Adults With Diabetes. Topics in Geriatric Rehabilitation 35:1, pages 31-41.
Crossref
Crossref
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding & Marc S Sabatine. (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet 393:10166, pages 31-39.
Crossref
Crossref
Jakob Starup-Linde & Søren Gregersen. 2020. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
1
26
.
Peter Vestergaard. 2020. Bone Regulators and Osteoporosis Therapy. Bone Regulators and Osteoporosis Therapy
475
497
.
G. M. NURULLINA, G. I. AKHMADULLINA, O. V. KRASNOPEROVA, M. M. ALEKSEEVA, O. V. ALEKSANDROVA & A. V. CHERNOVA. (2018) RISK FACTORS OF LOW-ENERGY FRACTURES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Kuban Scientific Medical Bulletin 25:4, pages 115-123.
Crossref
Crossref
İrfan Karahan, Çağar Alp & Aşkın Güngüneş. (2018) Sodium-glucose co-transporter-2 inhibitors in Type 2 diabetes treatment. Ortadoğu Tıp Dergisi 10:3, pages 381-385.
Crossref
Crossref
Hiddo J.L. Heerspink, Mikhail Kosiborod, Silvio E. Inzucchi & David Z.I. Cherney. (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney International 94:1, pages 26-39.
Crossref
Crossref
C. Ma, K. T. Tonks, J. R. Center, D. Samocha‐Bonet & J. R. Greenfield. (2018) Complex interplay among adiposity, insulin resistance and bone health. Clinical Obesity 8:2, pages 131-139.
Crossref
Crossref
Jagriti Upadhyay, Stergios A. Polyzos, Nikolaos Perakakis, Bindiya Thakkar, Stavroula A. Paschou, Niki Katsiki, Patricia Underwood, Kyung-Hee Park, Jochen Seufert, Eun Seok Kang, Elliot Sternthal, Asterios Karagiannis & Christos S. Mantzoros. (2018) Pharmacotherapy of type 2 diabetes: An update. Metabolism 78, pages 13-42.
Crossref
Crossref
T.D. Filippatos, V. Tsimihodimos, G. Liamis & M.S. Elisaf. (2018) SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 12:1, pages 59-63.
Crossref
Crossref
Jakob Starup-Linde & Søren Gregersen. 2018. Diabetes Complications, Comorbidities and Related Disorders. Diabetes Complications, Comorbidities and Related Disorders
411
436
.
Jakob Starup-Linde & Søren Gregersen. 2018. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment
1
27
.
Pravesh Kumar Bundhun, Girish Janoo & Feng Huang. (2017) Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials. BMC Pharmacology and Toxicology 18:1.
Crossref
Crossref
A. G. D. Vianna, C. P. Sanches & F. C. Barreto. (2017) Review article: effects of type 2 diabetes therapies on bone metabolism. Diabetology & Metabolic Syndrome 9:1.
Crossref
Crossref
Leyna Leite Santos, Fernando José Camello de Lima, Célio Fernando de Sousa-Rodrigues & Fabiano Timbó Barbosa. (2017) Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus. Revista da Associação Médica Brasileira 63:7, pages 636-641.
Crossref
Crossref
R. Todd Alexander & Henrik Dimke. (2017) Effect of diuretics on renal tubular transport of calcium and magnesium. American Journal of Physiology-Renal Physiology 312:6, pages F998-F1015.
Crossref
Crossref
G. Isanne Schacter & William D. Leslie. (2017) Diabetes and Bone Disease. Endocrinology and Metabolism Clinics of North America 46:1, pages 63-85.
Crossref
Crossref
Edoardo Mannucci & Matteo Monami. (2016) Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?. Drug Safety 40:2, pages 115-119.
Crossref
Crossref
H. L. Tang, D. D. Li, J. J. Zhang, Y. H. Hsu, T. S. Wang, S. D. Zhai & Y. Q. Song. (2016)
Lack of evidence for a harmful effect of sodium‐glucose co‐transporter 2 (
SGLT2
) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta‐analysis of randomized controlled trials
. Diabetes, Obesity and Metabolism 18:12, pages 1199-1206.
Crossref
Crossref
Angeliki M. Stamatouli & Silvio E. Inzucchi. (2016) Implications of the EMPA-REG Trial for Clinical Care and Research. Current Diabetes Reports 16:12.
Crossref
Crossref
André J. Scheen. (2016) SGLT2 Inhibitors: Benefit/Risk Balance. Current Diabetes Reports 16:10.
Crossref
Crossref
Hiddo J.L. HeerspinkBruce A. PerkinsDavid H. FitchettMansoor HusainDavid Z. I. Cherney. (2016) Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus. Circulation 134:10, pages 752-772.
Crossref
Crossref